SCHEDULE: Redmile Group Boosts ADC Therapeutics Stake to 14%

Redmile Group, LLC and its affiliates have increased their beneficial ownership in ADC Therapeutics SA to 14.0% of common shares outstanding.

Summary

• Redmile Group, LLC, along with its principal Jeremy C. Green, and RedCo II Master Fund, L.P., have reported significant beneficial ownership in ADC Therapeutics SA.
• Redmile Group, LLC and Jeremy C. Green each beneficially own 15,666,731 common shares, representing 14.0% of the class.
• RedCo II Master Fund, L.P. beneficially owns 13,145,712 common shares, representing 11.7% of the class.
• The percentages are calculated based on 99,178,286 common shares outstanding as of May 1, 2025, plus an additional 13,031,161 shares issued in a private placement as of June 16, 2025, totaling 112,209,447 shares.
• The reported beneficial ownership excludes shares issuable upon exercise of pre-funded warrants due to a 9.99% beneficial ownership limitation clause. Redmile Group and Mr. Green exclude 23,897,532 shares, while RedCo II excludes 18,599,071 shares from such warrants.
• The shares are held by private investment vehicles managed by Redmile Group, LLC, with shared voting and dispositive power.
• The filing states the securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a factual disclosure of beneficial ownership. The increase in stake by a specialized healthcare investor like Redmile Group could be viewed positively as a vote of confidence, but the filing itself does not contain operational or financial news to significantly shift sentiment beyond neutral.

Positives

• Increased significant institutional ownership by Redmile Group, a specialized healthcare investor, which can signal confidence in ADC Therapeutics SA.
• The investment is held by multiple entities managed by Redmile, indicating a structured and diversified approach to their stake.

Risks

• The beneficial ownership percentages are subject to change based on future transactions or changes in the total outstanding shares.
• The exclusion of pre-funded warrant shares due to a 9.99% beneficial ownership cap means the full potential stake is not immediately reflected, which could impact future share availability or dilution if those warrants were to be exercised without the cap.

Future Outlook

NA

Industry Context

This filing indicates continued or increased interest from a specialized healthcare investment firm in ADC Therapeutics, a company likely operating in the biotechnology or pharmaceutical sector. Such investments are common in the life sciences industry, where specialized funds often take significant stakes in promising companies.

Comparison to Industry Standards

• Redmile Group is a well-known investment firm specializing in healthcare. Their significant stake (14.0%) in ADC Therapeutics SA is a substantial position for an institutional investor in a publicly traded biotech company, often signaling a long-term strategic interest.
• The beneficial ownership cap (9.99%) on warrant exercise is a standard provision used by investors to avoid triggering certain regulatory thresholds (e.g., Section 13D reporting requirements, which are more stringent than 13G). This is a common practice among institutional investors to maintain flexibility while holding large potential stakes.

Stakeholder Impact

• Shareholders: Increased institutional ownership by a specialized fund may be perceived positively, potentially enhancing investor confidence and liquidity.
• Company Management: A significant institutional investor like Redmile Group may exert influence through engagement, though the filing states the stake is not for control purposes.

Key Dates

Keywords

ADC Therapeutics, Redmile Group, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Shares, Biotechnology, Healthcare Investment, SEC Filing, Shareholder Update